Absci Corporation · NASDAQ:ABSI
Absci — Investor Presentation (November 2025)
84 slides from Absci's investor presentation, Nov 12, 2025
Slide 1: Corporate Presentation Fall 2025
from absci import de_novo_model model = de_novo_model.load_latest() antigen = model.load_pdb("7olz.pdb", chain="A") antibodies = model.predict(antigen, N=300000) from absci_library import codon_optimizer library = codon_optimizer.reverse_translate(library) library.to_csv("covid-antibody-designs.csv"
Slide 2: Disclaimers
2C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Disclaimers Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Secu
Slide 3: Generative AI Drug Creation
3N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D .C P Y R I G H T © 2 0 2 5 A B S I C O R P O R A T I O N . A L L R I G H T S E S E R V E D . Generative AI Drug Creation™ D I F F E R E N T I A T E D P I P E L I N E A P R
Slide 4: High-quality data at scale for AI model training and validation
4C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Since 2020 Absci has been amassing high-quality data at scale for AI model training and validation DATA TO TRAIN Proprietary high throughput screening assays generate high- quality data for generative
Slide 5: Leadership in AI de novo design of antibody-based therapeutics
5C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Leadership in AI de novo design of antibody-based therapeutics EVQLSEVGA . . . De novo antibody design model creates epitope-specific binders given a target structure Designed in framework of choice or
Slide 6: We use AI to create novel & differentiated therapeutics
6C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ENABLING FEATURES: MULTI-VALENCY, pH-DEPENDENT BINDING ABILITY TO ADDRESS DIFFICULT TARGET CLASSES, E.G. GPCRS EPITOPE-SPECIFIC DESIGN + EPITOPE INTERFACE OPTIMIZATION POTENTIAL TO CREATE MEANINGFUL IP
Slide 7: Leveraging AI throughout the end-to-end drug discovery process
7C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Leveraging AI throughout the end-to-end drug discovery process I N T E G R A T E D D R U G C R E A T I O N P L A T F O R M TARGET SELECTION AI reverse immunology target discovery OR Additional Target S
Slide 8: de novo model progress 2022-2025
8C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . de novo Model v1 Absci was the first to design and validate novel antibodies using zero-shot generative AI in BioRxiv preprint de novo Model v2 Demonstrated de novo design model’s broad applicability t
Slide 9: Platform Case Studies
9C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Platform Case Studies AI LEAD OPTIMIZATIONDE NOVO ANTIBODY DESIGN Goal: Create universally neutralizing HIV antibody by binding conserved epitope within “Caldera” region of HIV gp120 Absci’s de novo de
Slide 10: Multilingual team with expertise in AI and drug creation
10C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ”Multilingual” team with expertise in AI and drug creation Sean McClain Founder, CEO & Director Andreas Busch, PHD Chief Innovation Officer Zach Jonasson, PHD Chief Financial Officer & Chief Business
Slide 11: Talent and infrastructure for better biologics faster
11C O P Y R I G H T © 2 0 2 4 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ~140 Employees 77,000+ Square Feet >$600M Trademarks, service marks or trade names referred to herein are the intellectual property of their respective owners. Use of this IP does not imply affiliatio
Slide 12: Advancing and expanding our pipeline of AI-designed assets
12C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Advancing and expanding our pipeline of novel & differentiated assets designed using AI KEY HIGHLIGHTS A I P I P E L I N E A B S - 2 0 1 ( A G A ) Ph1/2a study for androgenetic alopecia anticipated to
Slide 13: Track record of industry-leading partnerships
13C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . AI Drug Creation™ Data & compute 25+ PARTNERED PROGRAMS TO DATE SCALING COMPUTE 5 NAMED INTERNAL PROGRAMS ADDITIONAL PROGRAMS IN EARLY DEVELOPMENT IMPROVING MODELS INCREASING EFFICIENCIES Trademarks,
Slide 14: Near-term value inflection points
14C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Leading AI platform driving numerous near-term value inflection points A B S - 1 0 1 Phase 1 Interim Data reported Advancing partnering and out-licensing opportunities A B S - 2 0 1 i n A G A Accelera
Slide 15: ABS-201 AGA and Endo progress
15C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . A B S - 2 0 1 A G A Accelerated development of ABS-201 in androgenetic alopecia • Ph1/2a study initiation on track for Dec 2025 • Interim efficacy readout anticipated 2H 2026 A B S - 2 0 1 E n d o Ind
Slide 16: ABS-201 potential in hair re-growth
16C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201 has the potential to unlock a wholly new category of therapy in hair “re-growth” Significant unmet clinical need for androgenetic alopecia Large market: approximately 80 million patients in U.
Slide 17: Underserved androgenetic alopecia patient population
17C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Underserved patient population looking for therapeutic innovation FEMALE ANDROGENETIC ALOPECIA ~30M women in the U.S. Only 1 FDA approved therapy for women ~50M men in the U.S. Only 2 FDA approved the
Slide 18: PRLR inhibition as a safe innovative alternative
18C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . PRLR inhibition as a safe innovative alternative to current treatment options A B S - 2 0 1 | A G A P r o p o s e d d i r e c t i m p a c t o f A B S - 2 0 1 o n H a i r C y c l e S t a g e s A B S -
Slide 19: Prolactin impacts on organ-cultured human hair follicles
19C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Prolactin impacts on organ-cultured human hair follicles 1doi: 10.2353/ajpath.2006.050468 P r o l a c t i n - d r i v e s h a i r f o l l i c l e r e g r e s s i o n i n h u m a n e x v i v o c u l t
Slide 20: PRLR inhibition supported as safe by human genetics
20C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . PRLR inhibition anticipated to be safe & well tolerated as supported by human genetics A B S - 2 0 1 | A G A I. II. III. NV = Nonvariant ND = Not determined I. II. III. I. II. III. IV. Kobayashi, 2018
Slide 21: Anti-PRLR mAb promotes long-term hair growth in NHP
21C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Treatment with an anti-PRLR mAb promotes and sustains long-term hair growth in NHP TOP HEAD VIEW OF STUMPTAILED MACAQUE’S SHOWING PHENOTYPIC CHANGE OVER TIME 40mg/kg s.c. Q2W for 28 weeks Disclosure f
Slide 22: ABS-201 superior to minoxidil in hair regrowth model
22C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201 shows superior efficacy vs 5% topical minoxidil in 21d hair regrowth model Administration: mAbs i.p. biweekly; Minoxidil topical daily Untreated (n=11) Isotype (n=11) Minoxidil 5% (n=11) ABS-2
Slide 23: NHP PK data confirms extended half-life and bioavailability
23C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . 56 day NHP PK data confirms extended half-life profile and high SC bioavailability A B S - 2 0 1 | A G A >3x extended half-life in NHPs compared to HMI-115 High subcutaneous bioavailability in NHPs at
Slide 24: Modelling shows superiority of ABS-201 vs HMI-115
24C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201, 1800mg SC ABS-201, 1200mg SC ABS-201, 600mg SC ABS-201, 300mg SC RO for Ctrough of HED - monkey study RO for Ctrough – Ph1b HMI-115 RO for Ctrough – Ph2 HMI-115 Time (weeks) In te rs tit ia l
Slide 25: Potential best-in-class PRLR antibody for AGA
25C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Potential best-in-class PRLR antibody for treating androgenic alopecia (AGA) A B S - 2 0 1 | A G A AI-designed PRLR program for durable hair regrowth therapy addressing patient population of >80M in t
Slide 26: Superior profile of ABS-201
26C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . D E S I R E D A T T R I B U T E HMI-115 ABS-201 A F F I N I T Y + ++ I N V I T R O P O T E N C Y ++ ++ H I G H S O L U B I L I T Y - ++ S T A B I L I T Y - + E X T E N D E D ½ - L I F E - ++ B I O A V
Slide 27: Straightforward path for ABS-201 clinical development
27C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Straightforward path for ABS-201 clinical development C L I N I C A L T R I A L S F O R H A I R T R E A T M E N T S A R E E X P E C T E D T O B E S T R A I G H T F O R W A R D • Ease of patient recrui
Slide 28: Scientific Advisory Board of Hair Experts
28C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Leading Scientific Advisory Board of Hair Experts DR. ANTHONY ROSSI Memorial Sloan Kettering Cancer Center DR. CHESAHNA KINDRED Kindred Hair & Skin Center DR. MATT L. LEAVITT Advanced Dermatology and
Slide 29: Ph1/2a trial initiation expected December 2025
29C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Accelerated development with Ph1/2a trial initiation expected in December 2025 AI-designed development candidates ü High affinity ü High potency ü Favorable manufacturability ü Long half-life A I D E
Slide 30: ABS-201 Endo expansion and pipeline progress
30C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . A B S - 2 0 1 A G A Accelerated development of ABS-201 in androgenetic alopecia • Ph1/2ª study initiation anticipated Dec 2025 • Interim efficacy readout anticipated 2H 2026 A B S - 2 0 1 E n d o Indi
Slide 31: Expanded development of ABS-201 in Endometriosis
31C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Expanded development of ABS-201 in Endometriosis ADDRESSES LONG-STANDING UNMET MEDICAL NEED • Current therapies are palliative with poor tolerability • No disease-modifying options available • Affects
Slide 32: Endometriosis significantly impacts patients' quality of life
32C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Endometriosis significantly impacts patients Quality of Life Sources: PMID 40323608, PMID 18367178, ARTEMIS 2024 Report Endo: Endometriosis; QOL: Quality of life Endometriosis is a chronic, estrogen-
Slide 33: Endometriosis: a chronic and painful condition
33C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Endometriosis (Endo) – a chronic and painful condition A B S - 2 0 1 | E N D O M E T R I O S I S Endometrial tissue Pathogenesis involves seeding of ectopic endometrial cell lesions within the abdomin
Slide 34: Hormonal therapies and surgery make up the Endo treatment paradigm
34C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Hormonal therapies and surgical intervention make up the treatment paradigm for Endo • Endo is a chronic condition with currently no medical or surgical cure • Roughly, 75% of patients are estimated t
Slide 35: Pain remains a persistent, chronic issue
35C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . • Patients with Endo report ineffective pain management as a number one unmet need • Additionally, patients are seeking the ability to have children • The condition itself carries a higher risk for in
Slide 36: ABS-201 offers a novel modality in a stale paradigm
36C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201 offers a novel and differentiated modality in a stale treatment paradigm A B S - 2 0 1 | E N D O M E T R I O S I S PRL and PRLR play a dual role in endometrial lesion development and pain resp
Slide 37: PRL and PRLR overexpressed in endometriosis
37C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . PRL and PRLR increase during secretory phase in healthy tissue, and is overexpressed in endometrium of patients with endometriosis L O C A L I Z A T I O N A N D T E M P O R A L E X P R E S S I O N O F
Slide 38: PRLR antagonism suppresses pain and endometriosis formation in mice
38C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . PRLR antagonism suppresses postoperative pain in female mice and inhibits endometriosis interna formation Prolactin Regulates Pain Responses via a Female- Selective Nociceptor-Specific Mechanism The e
Slide 39: ABS-201 relieves pain and inflammation in mouse endometriosis model
39C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201 relieves pain and inflammation in a homologous transplant mouse model of endometriosis A B S - 2 0 1 | E N D O M E T R I O S I S ABS-201 and anti-GnRH treatment increase distance traveled rela
Slide 40: Quinagolide effects in endometriosis-associated hyperprolactinemia
40C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia A B S - 2 0 1 | E N D O M E T R I O
Slide 41: ABS-201 novel treatment option for Endometriosis
41C O P Y R I G H T © 2 0 2 4 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-201 offers a novel treatment option for patients with Endometriosis • Non–sex-steroid hormonal MOA • Potential for improved AE profile, longer duration of treatment over GnRH therapies • Potential
Slide 42: Little competition, potential best-in-class profile
42C O P Y R I G H T © 2 0 2 4 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Little competition, potential for “best-in-class” profile A B S - 2 0 1 | E N D O M E T R I O S I S Favorable competitive environment with clinical MOA recently de-risked by competitor • Phase 2 clini
Slide 43: ABS-201 AGA and Endo progress
43C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . A B S - 2 0 1 A G A Accelerated development of ABS-201 in androgenetic alopecia • Ph1/2ª study initiation anticipated Dec 2025 • Interim efficacy readout anticipated 2H 2026 A B S - 2 0 1 E n d o Indi
Slide 44: AI-designed TL1A antibody ABS-101 ready for partnering
44N O N - C O N F I D E N T I A L C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . AI Designed TL1A antibody in Ph1 Clinical development; ready for partnering ABS-101 Summary A B S - 1 0 1 T L 1 A No apparent impact of ADA on PK and the overall safety
Slide 45: Validated mechanism in large underserved market
45C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Validated mechanism of action in large underserved market A B S - 1 0 1 T L 1 A P O T E N T I A L R E L E V A N C E I N W I D E R A N G E O F A U T O I M M U N E I N D I C A T I O N S T L 1 A : D R 3
Slide 46: AI platform generates high affinity variants
46C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Successful application of AI platform to generate high affinity variants A B S - 1 0 1 T L 1 A H I G H A F F I N I T Y m A b s W I T H P R E S E R V E D C R O S S - R E A C T I V I T Y MK-7240 # RVT-3
Slide 47: High affinity and potential for superior potency
47C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . 1101001000 1 10 100 1000 Monom er Bind ing (pM) Tr im er B in di ng (p M ) No M onomer Bind ing H I G H A F F I N I T Y m A b s W I T H B I N D I N G T O B O T H T H E T L 1 A M O N O M E R A N D T R
Slide 48: Immunogenicity assessment: TL1A complex internalization
48C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Internalization of mAb:TL1A complexes potentially contributes to immune activation and formation of ADA A B S - 1 0 1 T L 1 A | I M M U N O G E N I C I T Y A S S E S S M E N T mAb only ABS-101-A RVT-3
Slide 49: NHP pharmacokinetics and CMC data
49C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . NHP Pharmacokinetics & CMC data A B S - 1 0 1 T L 1 A 2-3x extended half-life in NHPs over 1st generation clinical competitors ABS-101 shows enhanced biodistribution in NHPs, compared to antibodies in
Slide 50: ABS-101 NHP target engagement data
50C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . ABS-101 Non-Human Primate (NHP) data A B S - 1 0 1 T L 1 A ! "! #! A! %! &! '! !(" " "! "!! "!!! )*+, ,- ." L 01 23 4 5 !"#AB&B'B()*+,*'-K/K !"#AB&B'M&)*+,*'-K/K !"#AB&B'M&)*+,*'1K2K !"#AB&B'3&&)*+,*'
Slide 51: Phase 1 interim data reported; advancing partnership discussions
51C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Phase 1 Clinical trial interim data reported; advancing partnership discussions A B S - 1 0 1 T L 1 A AI-designed Development Candidate ü High affinity ü High potency ü Long half-life ü Favorable manu
Slide 52: ABS-201 AGA and Endo progress
52C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . A B S - 2 0 1 A G A Accelerated development of ABS-201 in androgenetic alopecia • Ph1/2ª study initiation anticipated Dec 2025 • Interim efficacy readout anticipated 2H 2026 A B S - 2 0 1 E n d o Indi
Slide 53: Tertiary lymphoid structures and clinical outcomes
53C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . The presence of TLS is associated with longer progression-free survival and better response to immune checkpoint inhibitors2,3. Rapidly growing evidence illustrates correlation between TLS-derived ant
Slide 54: Reverse Immunology platform identifies TLS antibody antigens
54C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . LIGHT CHAINS HEAVY CHAINS Samples collected from patients with high expression of TLS markers Antibody expression Immunoglobulin reads from RNAseq data Target identification using high throughput prot
Slide 55: ABS-301 rescues pro-inflammatory signaling
55C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . A B S - 3 0 1 r e s c u e s p r o - i n f l a m m a t o r y s i g n a l i n g t h r o u g h i n h i b i t i o n o f i m m u n o s u p p r e s s i v e c y t o k i n e A patient-derived antibody discove
Slide 56: In vivo target validation: anti-tumor response
56C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . In vivo Target Validation: Pathway Activation Drives Potent Anti-Tumor Response A B S - 3 0 1 Key Findings: Activation of the ABS-301–targeted pro-inflammatory pathway triggers a robust anti-tumor imm
Slide 57: Target expression across squamous cell carcinomas
57C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Expression of ABS-301’s target suggests broad potential in squamous cell carcinomas A B S - 3 0 1 Distribution of ABS-301 target expression across squamous cell carcinoma cohorts. ABS-301 target expre
Slide 58: Expression in lung squamous cell carcinoma
58C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Expression in Lung Squamous Cell Carcinoma (LUSC): no change with treatment and strong negative correlation with CD8+ T cell infiltration A B S - 3 0 1 In LUSC, univariate analysis of ABS-301 expressi
Slide 59: Preclinical studies exploring immuno-oncology applications
59C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Ongoing preclinical studies exploring broad application in immuno-oncology A B S - 3 0 1 Based on literature and potential competitive molecules, the following indications could be of interest: *depen
Slide 60: De novo AI model on HER2 discovers distinct antibodies
60C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . • Hits with edit distance of up to 12 amino acids in HCDR3 region (13 aa, search space of 2013) were screened • Selected 50 hits with <10 nM affinity were expressed as mAbs for binding affinity determ
Slide 61: AI-designed antibodies enhance ADCC activity vs trastuzumab
61C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Luciferase signal driven by NFAT transcription factor positively correlates to ADCC activation against JIMT-1 AI-designed antibodies demonstrate measurable enhancement of ADCC activity compared to tra
Slide 62: AI-designed antibodies suppress HER2+ breast tumor growth
62C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . AI-designed antibodies suppress growth of trastuzumab-sensitive & resistant HER2+ breast tumors A B S - 5 0 1 Partial Critical Not critical Trastuzumab WT Variant 1 Variant 3 Variant 4 Mouse xenograft
Slide 63: Opportunities to address unmet medical need
63C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . AI-designed antibodies create opportunities to address unmet medical need A B S - 5 0 1 Modality switch or combination opportunities under consideration to address unmet medical needs Later-line treat
Slide 64: Leading AI models to create novel & differentiated therapeutics
64C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Leading AI models to create novel & differentiated therapeutics “Smart” biologics Enhanced Potency & MOA Engineer selectivity, minimizing off target toxicity Agonism vs. Antagonism Bind Specific extra
Slide 65: Leadership in AI de novo design of antibody-based therapeutics
65C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Leadership in AI de novo design of antibody-based therapeutics EVQLSEVGA . . . De novo antibody design model creates epitope-specific binders given a target structure Designed in framework of choice o
Slide 66: AI platform designs, wet lab confirms
66C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . AI Platform designs antibodies Wet Lab confirms AI- designed antibodies maintain drug-like properties Wet Lab data improve models D E N O V O A N T I B O D Y D E S I G N Our AI platforms are enabled b
Slide 67: AbsciDesign AI models for de novo antibody design
67C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . AbsciGen: antibody<>antigen complex structure and sequence design AbsciBind: antibody design scoring and filtering Antigen AbsciGen AbsciBind AbsciBind High Rank RMSD = 2.3 Å Confidence = 0.95 AbsciBi
Slide 68: End-to-end design-validation workflow
68C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . STEP 1. Define design parameters STEP 2. Fine-tune and deploy AbsciGen and AbsciBind to generate hundreds of thousands of variants and filter to a subset that are likely binders STEP 3. Wet lab screen
Slide 69: Case study: de novo design of antibody binding HIV Caldera
69C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . C A S E S T U D Y de novo design of an antibody that binds the Caldera region of HIV-1 trimer
Slide 70: No universally neutralizing HIV antibody exists today
70C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . No natural or synthetic antibody for HIV exists today because immune system cannot derive an antibody that is universally neutralizing against HIV Design challenge: create universally neutralizing HIV
Slide 71: HIV-Caldera: determine inputs and design
71C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . HIV-Caldera: Determine inputs and design D E N O V O D E S I G N HIV Env Trimer Challenge : • Highly glycosylated • Extremely high sequence diversity among isolates • High mutation rate at common neut
Slide 72: Best structures selected from 10,000+ generated
72C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . 4 best structures selected from 10,000+ structures generated by de novo model D E N O V O D E S I G N 17b Structure S1 HCDR3 Structure S3 HCDR3 Structure S2 HCDR3 Structure S4 HCDR3 HeavyLight
Slide 73: Molecular dynamics simulation of de novo designed antibodies
73C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Applied molecular dynamics simulation to de novo designed antibodies D E N O V O D E S I G N
Slide 74: Enriched library binds open Env trimer
74C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . H A ta g Antigen Clade A Env trimer Closed Open Enriched de novo library binds open, not closed, Env trimer conformation in YSD D E N O V O D E S I G N Closed Open Clade B Env trimer
Slide 75: SPR data consistent with caldera binding
75C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . SPR data demonstrate binding characteristics consistent with binding of caldera D E N O V O D E S I G N
Slide 76: SPR shows no binding to GP120 monomer
76C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . HIV-Caldera: SPR demonstrates no binding of de novo designs to GP120 monomer D E N O V O D E S I G N Hypothesis: If the designed mAbs are binding to the caldera region we should not observe binding to
Slide 77: AI de novo design for a challenging target
77C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . HIV-Caldera: demonstrating AI de novo design for challenging target H I V D E N O V O D E S I G N SUMMARY de novo design model created a novel and diverse antibody which binds multiple clades of HIV i
Slide 78: Case study: AI optimization for pH sensitivity
78C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . CASE STUDY A I O p t i m i z a t i o n f o r p H s e n s i t i v i t y
Slide 79: AI lead optimization for pH sensitivity
79C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . C A S E S T U D Y – A I L E A D O P T I M I Z A T I O N f o r p H S E N S I T I V I T Y AI lead optimization platform for ‘smart biologics’ T H E C H A L L E N G E : The diversity of antibodies is vas
Slide 80: Tumor specificity improves efficacy and reduces toxicity
80C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . TUMOR SPECIFICITY IMPROVES EFFICACY AND REDUCES ”ON-TARGET OFF-TUMOR” TOXICITIES pH sensitivity may reduce toxicity and/or improve efficacy of therapeutic mAbs C A S E S T U D Y - A I L E A D O P T I
Slide 81: Models identify pH sensitive Fab variants
81C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Models identify pH sensitive Fab variants from the same lead for either indication C A S E S T U D Y - A I L E A D O P T I M I Z A T I O N F O R p H S E N S I T I V I T Y 1. Library for model training
Slide 82: Hits reformatted as mAbs show desired binding profiles
82C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . Hits reformatted as mAbs show desired binding profiles C A S E S T U D Y - A I L E A D O P T I M I Z A T I O N F O R p H S E N S I T I V I T Y AI optimized leads achieves variants with pH sensitive bi
Slide 83: Summarized platform case studies
83C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . D E N O V O D E S I G N de novo design model created molecule binds multiple clades of HIV suggesting successful targeting of the caldera epitope Represents second disclosed target success for our de
Slide 84: Better biologics for patients, faster
Better biologics for patients, faster 84C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D .